Selected RhD topics presented during the 23rd Regional Congress of the International Society of Blood Transfusion in Amsterdam
Monika Pelc-Kłopotowska, Ewa Brojer
Journal of Transfusion Medicine 2013;6(3):105-108.
open access
Vol 6, No 3 (2013)
REVIEWS
Abstract
Not available
Abstract
Not available
Get Citation
About this articleTitle
Selected RhD topics presented during the 23rd Regional Congress of the International Society of Blood Transfusion in Amsterdam
Journal
Journal of Transfusion Medicine
Issue
Pages
105-108
Bibliographic record
Journal of Transfusion Medicine 2013;6(3):105-108.
Authors
Monika Pelc-Kłopotowska
Ewa Brojer
References (15)- Wagner F. RhesusBase v2: a versatile source of information on published RHD alleles. Vox Sang. 2013; 105(supl. 1): 1–64.
- Meshi A. Characterisation of antigenicity of an RhD peptide mimotope and assessment of its immunogenicity in HLA-DR15 transgenic mice. Vox Sang. 2013; 105(supl. 1): 1–64.
- Hall S, Hall M, Pickford J, et al. Combination peptide immunotherapy suppresses antibody and helper T cell responses to the RhD protein in HLA-transgenic mice. Vox Sang. 2013; 105(supl. 1): 65–299.
- Hall AM, Cairns LS, Altmann DM, et al. Immune responses and tolerance to the RhD blood group protein in HLA-transgenic mice. Blood. 2005; 105(5): 2175–2179.
- Tan JC, Armstrong NJ, Yuan FF, et al. Genetic polymorphisms and immune response pathways associated with different responder profiles of RhD immunized blood donors. Vox Sang. 2013; 105(supl. 1): 1–64.
- Verduin EP, Schonewille H, Claas F, et al. HLA-DRB1*15 is a marker for multiple antibody responders. Vox Sang. 2013; 105(supl. 1): 1–64.
- Hong YJ, Chang HE, Hwang SM, et al. Molecular characteristics of partial D in Korea. Vox Sang. 2013; 105(supl. 1): 65–299.
- Silvy M, Granier T, Beley S, et al. First comprehensive investigation of both RHD and RHCE allele distribution in Sub-Saharan Africa: the clinical implications for transfusion medicine. Vox Sang. 2013; 105(supl. 1): 65–299.
- Hyland A, Gardener J, et al. O’Brien H. Managing diverse maternal RHD variants in alloimmunised and non-alloimmunised D negative pregnant women during fetal RHD genotyping. Vox Sang. 2013; 105(supl. 1): 1–64.
- Trucco Boggione C, Lujan Brajovich M, Tarrago M, et al. Molecular structures identified in serologically D negative samples of an admixed population. Vox Sang. 2013; 105(supl. 1): 1–64.
- Veldhuisen B, Thurik F, Jonkers R, et al. Molecular RHD variation of serological RhD negative women: implications for a fetal RHD screening programme to target anti-D prophylaxis. Vox Sang. 2013; 105(supl. 1): 1–64.
- Pisacka M, Sklenarova M, Kralova M, et al. VII: the most frequent partial D in Czech population with ‘Hidden Iceberg” real incidence: Results of a proficiency survey and D Variant Database in UHKT. Vox Sang. 2013; 105(supl. 1): 65–299.
- Figueiredo M, Chumakova A, Pereira J, et al. Being positive can be negative identification of a partial DIIIc. Vox Sang. 2013; 105(supl. 1): 65–299.
- Polin H, Ulrich S, Lanzer G, et al. RHD*WEAK D type 48 is prevalent in Southern Austria. Vox Sang. 2013; 105(supl. 1): 65–299.
- Castilho L, Machado D, Torres KB, et al. Jr. Anti-D in patients expressing weak D type 2. Vox Sang. 2013; 105(supl. 1): 65–299.